LONDON: Britain has authorised a gene therapy that aims to cure sickle-cell disease and another type of inherited blood disorder for patients aged 12 and over, the country's medical regulator said on Thursday, becoming the first in the world to do so.
Casgevy is the first medicine to be licensed that uses the gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020, Britain's Medicines and Healthcare products Regulatory Agency (MHRA) said.
Sickle cell disease and β-thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body.
"Both sickle cell disease and β-thalassemia are painful, life-long conditions that in some cases can be fatal," MHRA Interim Director Julian Beach said in the statement.
In clinical trials Casgevy has been found to restore healthy haemoglobin production in the majority of participants with sickle-cell disease and transfusion-dependent β -thalassaemia, relieving the symptoms of disease, Beach added.
The MHRA said no significant safety concerns were identified during the trials, adding that it was closely monitoring the safety of the medicine.
The medicine is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow.
U.S.-based companies Vertex Pharmaceuticals and CRISPR Therapeutics welcomed the approval in a separate statement.
"I hope this represents the first of many applications of this Nobel Prize winning technology to benefit eligible patients with serious diseases," said CRISPR CEO Samarth Kulkarni said.
Reuters
Thu Nov 16 2023
Sickle cell disease and β-thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body. - TWITTER
Kitaro di Festival Muzik Hutan Hujan Dunia 2024
Kitaro bakal membuat persembahan pada Festival Muzik Hutan Hujan Dunia (RWMF) 2024 pada 28-30 Jun ini.
PH kerja keras pertahan DUN KKB, tidak mahu berasa selesa
Walaupun berjaya menguasai kerusi Dewan Undangan Negeri (DUN) Kuala Kubu Baharu (KKB) selama tiga penggal sejak 2013, namun ia bukanlah tiket untuk Pakatan Harapan (PH) berasa selesa.
MDKpr nafi curi haiwan ternakan dalam kandang
Ahmad Suqairy berkata haiwan itu ditangkap dalam operasi oleh Bahagian Penguatkuasaan MDKpr pada 23 Apr lalu di kawasan Kolej TAR.
488 acara dipertandingkan di SUKMA Sarawak 2024 - MSN
Jawatankuasa Tertinggi Sukan Malaysia (SUKMA) secara rasmi bersetuju menawarkan sejumlah 488 acara dipertandingkan pada temasya SUKMA Sarawak 2024.
Petronas Dagangan catat jualan lebih 16 bilion liter bahan api pada 2023
PDB merekodkan peningkatan perolehan sebanyak dua peratus didorong jumlah jualan lebih tinggi dan keuntungan selepas cukai yang meningkat.
Aset rizab rasmi Malaysia berjumlah AS$113.76 bilion pada akhir Mac - BNM
Aset rizab rasmi Malaysia berjumlah AS$113.76 bilion pada akhir Mac 2024 manakala aset mata wang asing lain adalah US$1.61 bilion, kata Bank Negara Malaysia (BNM).
Kemunculan Momota di gelanggang pastinya dirindui - Pemain badminton dunia
Momota bakal bersara daripada arena sukan badminton antarabangsa selepas Piala Thomas 2024 yang sedang berlangsung di Chengdu.
Akta Sewaan Kediaman perlu digubal segera bagi pelihara hak pemilik, penyewa
Pertubuhan Sewaan Kediaman Kebangsaan hari ini meminta kerajaan menggubal Akta Sewaan Kediaman dengan segera bagi memastikan hak pemilik kediaman dan penyewa sentiasa terpelihara di negara ini.
Perkhidmatan komuter percuma sempena Program MADANI Rakyat Zon Utara
Langkah itu bagi memudahkan pengunjung di utara tanah air untuk datang memeriahkan program yang berlangsung tiga hari bermula Jumaat itu.
Nur Shazrin masih plilhan utama ke Paris - MSA
MSA tidak mahu menekan 'butang panik' selepas atletnya Nur Shazrin berdepan kemungkinan terlepas aksi di Sukan Olimpik Paris 2024 berikutan kecederaan berulang pada tangan kanannya.